AR122286A1 - Anticuerpos potenciadores del factor h y usos de estos - Google Patents
Anticuerpos potenciadores del factor h y usos de estosInfo
- Publication number
- AR122286A1 AR122286A1 ARP200102011A ARP200102011A AR122286A1 AR 122286 A1 AR122286 A1 AR 122286A1 AR P200102011 A ARP200102011 A AR P200102011A AR P200102011 A ARP200102011 A AR P200102011A AR 122286 A1 AR122286 A1 AR 122286A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequence
- seq
- nucleic acid
- antibody
- heavy chain
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 2
- 102000016550 Complement Factor H Human genes 0.000 abstract 2
- 108010053085 Complement Factor H Proteins 0.000 abstract 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 2
- 101710184994 Complement control protein Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un anticuerpo aislado, sintético o recombinante o un fragmento de unión al antígeno de este que se une específicamente al dominio de la proteína de control del complemento 18 (CCP18) del factor H (FH) que comprende lo siguiente: una secuencia de CDR1 de cadena ligera que comprende la secuencia SSVTY (SEQ ID nº 1) o la secuencia TSVTY (SEQ ID nº 13), una secuencia de CDR2 de cadena ligera que comprende la secuencia ATS (SEQ ID nº 2) o la secuencia ASS (SEQ ID nº 14), una secuencia de CDR3 de cadena ligera que comprende la secuencia QHRSSSNPLT (SEQ ID nº 3), una secuencia de CDR1 de cadena pesada que comprende la secuencia GFSLTNYG (SEQ ID nº 5), una secuencia de CDR2 de cadena pesada que comprende la secuencia VWSGGTT (SEQ ID nº 6) o la secuencia de IWSGGTT (SEQ ID nº 10) y una secuencia de CDR3 de cadena pesada que comprende la secuencia ARNFGNYAMDY (SEQ ID nº 7) o la secuencia ARNFGNYAMDF (SEQ ID nº 11). Reivindicación 21: Un ácido nucleico aislado, sintético o recombinante que comprende una secuencia de ácido nucleico que codifica el anticuerpo o fragmento según cualquiera de las reivindicaciones 1 a 20. Reivindicación 22: Un vector que comprende un ácido nucleico según la reivindicación 21. Reivindicación 25: Una célula recombinante que comprende el ácido nucleico según la reivindicación 21 o el vector según cualquiera de las reivindicaciones 22 - 24. Reivindicación 26: Una composición farmacéutica que comprende el anticuerpo o fragmento según cualquiera de las reivindicaciones 1 a 20, el ácido nucleico según la reivindicación 21, el vector según cualquiera de las reivindicaciones 22 - 24 o la célula recombinante según la reivindicación 25 y un portador, diluyente y/o excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875309P | 2019-07-17 | 2019-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122286A1 true AR122286A1 (es) | 2022-08-31 |
Family
ID=74211270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102011A AR122286A1 (es) | 2019-07-17 | 2020-07-17 | Anticuerpos potenciadores del factor h y usos de estos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11820814B2 (es) |
| EP (1) | EP3999073A4 (es) |
| JP (1) | JP7631296B2 (es) |
| KR (1) | KR20220057530A (es) |
| CN (1) | CN114828886B (es) |
| AR (1) | AR122286A1 (es) |
| AU (1) | AU2020313981A1 (es) |
| BR (1) | BR112022000739A2 (es) |
| CA (1) | CA3147638A1 (es) |
| IL (1) | IL289812A (es) |
| MX (1) | MX2022000725A (es) |
| TW (1) | TWI851771B (es) |
| WO (1) | WO2021011903A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250171487A (ko) * | 2018-01-15 | 2025-12-08 | 스티흐팅 산퀸 불드포르지닝 | 인자 h 강화 항체 및 이의 사용 |
| AU2021293174A1 (en) | 2020-06-14 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Complement Factor I-related compositions and methods |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
| WO2006012621A2 (en) | 2004-07-23 | 2006-02-02 | University Of Virginia Patent Foundation | Compositions and methods for regulating the alternative pathway of complement |
| EP2500030B2 (en) | 2005-11-04 | 2018-08-08 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| FR2894145B1 (fr) | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
| JP5683265B2 (ja) | 2007-06-07 | 2015-03-11 | ジェネンテック， インコーポレイテッド | 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法 |
| GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
| WO2011047146A2 (en) | 2009-10-14 | 2011-04-21 | Centocor Ortho Biotech Inc. | Methods of affinity maturing antibodies |
| US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| EP2616092B1 (en) | 2010-09-15 | 2018-01-24 | Celldex Therapeutics, Inc. | Treatment of chronic nephropathies using soluble complement receptor type i (scr1) |
| WO2013078223A1 (en) | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| US9926366B2 (en) | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
| GB201318170D0 (en) * | 2013-10-14 | 2013-11-27 | Univ Edinburgh | Proteins with Diagnostic and Therapeutic Uses |
| CN105705517A (zh) | 2013-11-07 | 2016-06-22 | 诺和诺德股份有限公司 | 用于治疗凝血障碍的新方法和抗体 |
| US10357554B2 (en) | 2013-11-11 | 2019-07-23 | The United States Of America, As Represented By The Secretary Of The Army | AMA-1 epitopes, antibodies, compositions, and methods of making and using the same |
| WO2016028150A1 (en) * | 2014-08-20 | 2016-02-25 | Stichting Sanquin Bloedvoorziening | Factor h potentiating antibodies and uses thereof |
| WO2016033225A2 (en) | 2014-08-27 | 2016-03-03 | Memorial Sloan Kettering Cancer Center | Antibodies, compositions, and uses |
| US20190071477A1 (en) * | 2015-12-31 | 2019-03-07 | Quassia Biopharma Co., Ltd | Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof |
| IL295288B2 (en) * | 2016-04-04 | 2024-08-01 | Bioverativ Usa Inc | Anti-complement factor BB antibodies and their uses |
| GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| AU2017289214B2 (en) * | 2016-06-28 | 2021-11-18 | Universität Ulm | Complement inhibitors and uses thereof |
| US10865238B1 (en) * | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
| KR20250171487A (ko) | 2018-01-15 | 2025-12-08 | 스티흐팅 산퀸 불드포르지닝 | 인자 h 강화 항체 및 이의 사용 |
-
2020
- 2020-07-17 JP JP2022503450A patent/JP7631296B2/ja active Active
- 2020-07-17 CA CA3147638A patent/CA3147638A1/en active Pending
- 2020-07-17 MX MX2022000725A patent/MX2022000725A/es unknown
- 2020-07-17 BR BR112022000739A patent/BR112022000739A2/pt unknown
- 2020-07-17 AU AU2020313981A patent/AU2020313981A1/en active Pending
- 2020-07-17 EP EP20840846.8A patent/EP3999073A4/en active Pending
- 2020-07-17 WO PCT/US2020/042627 patent/WO2021011903A1/en not_active Ceased
- 2020-07-17 CN CN202080063736.7A patent/CN114828886B/zh active Active
- 2020-07-17 AR ARP200102011A patent/AR122286A1/es unknown
- 2020-07-17 US US17/627,503 patent/US11820814B2/en active Active
- 2020-07-17 KR KR1020227005261A patent/KR20220057530A/ko active Pending
- 2020-07-17 TW TW109124345A patent/TWI851771B/zh active
-
2022
- 2022-01-12 IL IL289812A patent/IL289812A/en unknown
-
2023
- 2023-10-16 US US18/487,297 patent/US20240336676A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI851771B (zh) | 2024-08-11 |
| CN114828886A (zh) | 2022-07-29 |
| CA3147638A1 (en) | 2021-01-21 |
| WO2021011903A1 (en) | 2021-01-21 |
| KR20220057530A (ko) | 2022-05-09 |
| JP7631296B2 (ja) | 2025-02-18 |
| EP3999073A4 (en) | 2023-07-26 |
| MX2022000725A (es) | 2022-04-26 |
| EP3999073A1 (en) | 2022-05-25 |
| JP2022541275A (ja) | 2022-09-22 |
| US20240336676A1 (en) | 2024-10-10 |
| US20220372120A1 (en) | 2022-11-24 |
| BR112022000739A2 (pt) | 2022-04-12 |
| CN114828886B (zh) | 2025-04-18 |
| TW202110893A (zh) | 2021-03-16 |
| AU2020313981A1 (en) | 2022-03-03 |
| AU2020313981A8 (en) | 2024-05-30 |
| IL289812A (en) | 2022-03-01 |
| US11820814B2 (en) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| PE20251579A1 (es) | Anticuerpos especificos para cd70 y sus usos | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| CO2018011663A2 (es) | Nticuerpos anti-basigin humanizados y uso de los mismos | |
| AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| PE20230682A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| AR103839A1 (es) | DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| RU2021128024A (ru) | Способы культивирования клеток | |
| AR125451A1 (es) | Anticuerpos anti-clec12a y usos de los mismos | |
| AR130641A1 (es) | Anticuerpos anti-cd28 |